Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma have?
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma has 558 citations in the OpenAlex counts ScholarIQ stores.
When was Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma published?
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma has 2022 year in the ScholarIQ index.
What is the open-access status of Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma?
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma has bronze oa status in the ScholarIQ index.
What is the DOI of Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma?
The DOI for Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma is on the source record.
What is the PMID of Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma?
The PMID for Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma is on the source record.
What is the OpenAlex record for Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma?
The OpenAlex for Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma is on the source record.